Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. (Q36421292)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. |
scientific article |
Statements
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro (English)
Stefania Bellone
Jonathan Black
Diana P English
Carlton L Schwab
Emiliano Cocco
Federica Predolini
Francesca Ferrari
Elena Ratner
Dan-Arin Silasi
Masoud Azodi
Peter E Schwartz
Alessandro D Santin
10 August 2015
1 reference
1 reference
1 reference